Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GVAX (Cell Genesys).

R Dummer1

  • 1Department of Dermatology, University Hospital of Zürich, Switzerland. dummer@derm.unizh.ch

Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
PubMed
Summary
This summary is machine-generated.

GVAX, a cancer vaccine developed by Cell Genesys, is undergoing clinical trials for multiple tumor types. A high-potency version is now in trials following positive early results for this promising cancer immunotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.

ESMO open·2026
Same author

Five-year survival with tebentafusp in metastatic uveal melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: Incidence, management and therapy-A multicentre analysis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Operational classification of cutaneous squamous cell carcinomas based on unsupervised clustering of real cases by experts.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy
  • Vaccine Development

Background:

  • Cell Genesys is developing GVAX, a cancer vaccine.
  • GVAX targets various tumor types including melanoma, renal, lung, pancreatic, prostate cancers, and multiple myeloma.
  • The company was formerly known as Somatix Therapy Corp.

Purpose of the Study:

  • To evaluate the efficacy and safety of GVAX cancer vaccine across multiple cancer types.
  • To assess a high-potency version of GVAX for prostate cancer.
  • To explore GVAX applications through clinical trials and collaborations.

Main Methods:

  • Clinical trials for GVAX have been initiated for several cancer types.
  • Phase I and II trials are planned for leukemia and pancreatic cancer.

Related Experiment Videos

  • A collaboration with Japan Tobacco is in place for prostate cancer trials, with potential expansion.

    • Main Results:

    • Encouraging Phase II data has been reported for the first-generation GVAX prostate cancer vaccine.
    • A high-potency version of GVAX, releasing increased immune stimulants, has entered trials.
    • Japanese clinical trials were temporarily halted due to cell production issues.

    Conclusions:

    • GVAX shows potential as a cancer vaccine for various malignancies.
    • Further clinical development, including a high-potency formulation, is ongoing.
    • The development of GVAX highlights advancements in cancer immunotherapy.